LON:APTA

Aptamer Group Final Earnings Results & Report

Aptamer Group logo
GBX 0.30 -0.02 (-6.77%)
As of 11/18/2026 12:16 PM Eastern

Aptamer Group reported Final earnings on October 14, 2025. The company reported EPS of GBX 0.14.

Earnings Announcement Details

Quarter
Final
Report Date
Time
Before Market Opens

Aptamer Group EPS Results

Actual EPS
GBX 0.14
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Aptamer Group Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Conference Call Resources

Aptamer Group Final Earnings FAQ

Aptamer Group (LON:APTA) reported earnings of GBX 0.14 per share for Final. The report was announced on Tuesday, October 14, 2025.

Aptamer Group Earnings Headlines

The investigation Porter spent tens of thousands to document
Porter Stansberry flew the Porter and Co. team 3,300 miles to Dublin to investigate a 17-year investing experiment called Project Prophet - and documented everything on film. Rooted in the laws of physics, this quantitative approach challenges conventional wealth-building wisdom. With 17 years of verified data behind it, Porter calls it unlike anything he has seen in nearly 30 years in the business.tc pixel
Aptamer Group Regulatory News
Aptamer Group PLC
See More Aptamer Group Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Aptamer Group? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Aptamer Group and other key companies, straight to your email.

About Aptamer Group

Aptamer Group (LON:APTA) is a leading provider of aptamer selection services and developer of aptamer-based reagents for use in research, bioprocessing, diagnostic, and therapeutic applications. Headquartered in York, UK, the Company partners globally to deliver aptamer-based solutions that drive discovery and development across the life sciences. Aptamer Group has developed the proprietary Optimer® platform technology that drives three distinct businesses: Aptamer Solutions, Aptamer Diagnostics and Aptamer Therapeutics. Through the use of its Optimer platform the Company aims to enable new opportunities, including discovery and development partnerships for improved biologic drugs, and new applications, such as novel assays and targets, to accelerate discovery and improve current standard processes. For more information, visit: https://aptamergroup.com/

View Aptamer Group Profile